Systemic EBV-positive T/NK-cell lymphoproliferative diseases
Conditions
Interventions
Gold Standard:Clinical outcome
Index test:The 
model 
of 
systemic 
Epstein 
Barr 
NK 
cell 
lymphoproliferative 
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
No minimum to 100 Years
Inclusion criteria
Inclusion criteria: 2009-2017 1. Patients with diagnosis of systemic EBV+T/NK-LPDs according to 2017 WHO classification at the time of biopsy or with follow-up data. 2018-2019 1.Patients with diagnosis of systemic EBV+T/NK-LPDs according to 2017 WHO classification at the time of biopsy. 2.Morphology, phenotype,and laboratory test met the diagnostic criteria of systemic EBV+T/NK-LPDs, but the clinical course was less than 3 months (met the followed criteria of "a", and one of the "b","c","d","e") (1) ruled out ENKTL or ANKL; (2) monoclonal TR rearrangement; (3) accompanied with HLH or clinically suspected HLH; (4) symptoms lasted for 6 weeks without improvement; (5) lesions of organs other than lympho-hematopoietic system.
Exclusion criteria
Exclusion criteria: 1. Patients with other tumors; 2. Patients with other serious diseases (HIV infection, congenital or genetic diseases with risk of death).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival;Hb;splenomegaly;morphology;IHC result;SEN, SPE, ACC, AUC of ROC, PPV, NPV; | — |
Countries
China
Contacts
Public ContactZihang Chen
West China Hospital of Sichuan University
Outcome results
None listed